July 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” This study identifies GZL626, a first-in-class degrader of the androgen receptor N-terminal domain, which may overcome resistance in advanced prostate cancer by targeting both full-length and variant receptors.
January 2026 in “American Journal of Medical Genetics Part A” The researchers reported two brothers with a new variant of X-linked trichothiodystrophy associated with an RNF113A gene mutation, highlighting features such as intellectual disability and growth failure, but without previously reported endocrinological or genital abnormalities, underlining the importance of genetic counseling for such variants.